Streptococcus agalactiae Infection Models

Streptococcus agalactiae (S. agalactiae), or group B Streptococcus (GBS), is a Gram-positive bacterium and the leading cause of neonatal sepsis and meningitis. It colonizes the vaginal and gastrointestinal tract of a substantial share of healthy adults, and it is that maternal colonization that drives its most serious disease: transmitted to the newborn around delivery, GBS causes early- and late-onset neonatal bloodstream infection, meningitis, and pneumonia, and it is responsible for an estimated 100,000 infant deaths worldwide each year. Pregnant women are themselves susceptible to GBS bacteremia, amnionitis, and urinary tract infection, and the organism can cause stillbirth.

Beyond the perinatal setting, GBS is an increasingly common cause of invasive disease in older adults and people with diabetes or other comorbidities. Prevention currently rests on screening pregnant women and giving intrapartum antibiotic prophylaxis, and vaccines are in clinical development. The CDC classifies clindamycin-resistant group B Streptococcus as a concerning threat, and the WHO added S. agalactiae to the medium-priority tier of its 2024 Bacterial Priority Pathogens List, citing a concerning rise in β-lactam resistance. TransPharm Preclinical Solutions can develop and validate a custom S. agalactiae infection model to a program’s specifications.

The scientific problem in an S. agalactiae program is that its disease spans several compartments and a uniquely perinatal epidemiology, so the model has to be built to the question. GBS causes bloodstream infection and sepsis, meningitis, pneumonia, and urinary tract infection – presentations that map directly onto the infection models TransPharm Preclinical Solutions runs for other pathogens – and its central clinical problem is vertical transmission and neonatal disease.

Strain choice matters as well: GBS capsular serotype is tied to disease (serotype III, for example, is strongly associated with neonatal meningitis), and a susceptible reference isolate and a macrolide- or clindamycin-resistant or reduced-penicillin-susceptibility isolate answer different questions. Because there is no off-the-shelf validated GBS model on the current platform, the model, host, strain, and endpoints are defined together at the outset of a program.

TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized S. agalactiae isolates, including defined serotypes and resistant phenotypes, to a program’s specifications.

S. agalactiae is validated on request rather than as a fixed model, and its principal presentations align with TransPharm Preclinical Solutions’s established model platform: bloodstream infection (bacteremia and sepsis), central-nervous-system infection (an intracranial model of meningitis), pulmonary infection, and urinary tract infection. Any of these can be developed and validated for GBS, with challenge strain, host species and strain, route of administration, comparators, dosing, and endpoints configured to the program. The core readouts are quantitative bacterial burden (CFU) in target tissues, organs, and blood, with survival and mortality tracking where applicable, and pharmacokinetic profiling, blood chemistry, additional tissue harvests, and histopathology available as add-ons. Contact TransPharm Preclinical Solutions to scope a study design suited to your candidate.

Group B Streptococcus has, until recently, remained reliably susceptible to penicillin, which is first-line both for treating infection and for intrapartum prophylaxis. That is now under pressure from two directions. First, isolates with reduced penicillin susceptibility – driven by mutations in penicillin-binding proteins, particularly PBP2x – have emerged, which is the trend the WHO flagged in listing the organism. Second, and more established, resistance to the main alternative agents is high: erythromycin resistance runs from roughly a third of isolates to well over half in some regions, and clindamycin resistance – conferred by ribosomal methylation (erm) and efflux (mef) genes – is common enough that the CDC designates clindamycin-resistant GBS a concerning threat. Because clindamycin is the recommended prophylaxis for penicillin-allergic mothers (erythromycin is generally avoided for this indication because resistance is so common), its erosion has direct consequences for preventing neonatal disease. The resistance profile and serotype of the challenge strain therefore shape what a GBS efficacy study can demonstrate.